Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (Rophibio Co., Ltd), 度普利尤单抗生物类似药(Rophibio Co., Ltd), RBS 002 + [2] |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), IL-4 inhibitors(Interleukin-4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammation | Preclinical | South Korea | 26 Feb 2024 |






